Amgen Stock Hits Day Low of $344.95 Amid Price Pressure

Amgen, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, experienced a notable decline of 3.69% on March 20, 2026, reaching an intraday low of USD 344.95. This performance contrasts with the S&P 500, which fell by 1.51% on the same day. Over the past week, Amgen's stock has decreased by 7.9%, while its monthly performance shows a decline of 8.41%. Despite these short-term fluctuations, Amgen has demonstrated resilience over the past year, with a return of 9.15%, although this lags behind the S&P 500's 14.9% gain. Year-to-date, the stock has increased by 6.26%, outperforming the S&P 500's decline of 4.95%. Amgen's financial metrics indicate strong management efficiency, highlighted by a return on capital employed (ROCE) of 22.31%. The company maintains a robust dividend per share of USD 4.3 and a high interest coverage ratio of 777.03. With institutional holdings at 81.91%, Amgen continues to be a significant entity in its industry, despite the recent stock performance challenges.